Literature DB >> 9056592

The multivariate assessment of bioequivalence.

V M Chinchilli1, R K Elswick.   

Abstract

We propose an approach for comparing directly the reference and test blood concentration x time profiles of subjects in a bioequivalence trial under a crossover design. We compare the test and reference profiles via the construction of two regions, namely, an acceptable region based on the reference profile and another region based on reflecting the test profile about the reference profile. Also, we describe how to construct these regions if the assay for measuring the concentration has a lower limit of detection and how to adjust the reference and test concentrations of the n subjects participating in a bioequivalence trial. If the test and reference formulations are bioequivalent, then the area displaced by the latter region should be less than the area displaced by the acceptable region. Therefore, we construct a ratio of these areas for each subject. Then we calculate upper confidence limits for quantiles, either under theassumption of lognormality or based on a bootstrapping algorithm, to investigate population and/or individual bioequivalence.

Mesh:

Year:  1997        PMID: 9056592     DOI: 10.1080/10543409708835173

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  6 in total

1.  Novel direct curve comparison metrics for bioequivalence.

Authors:  J E Polli; A M McLean
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

2.  When is a metric not a metric? Remarks on direct curve comparison in bioequivalence studies.

Authors:  Wojciech Jawień
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-06-21       Impact factor: 2.745

3.  Evaluation of direct curve comparison metrics applied to pharmacokinetic profiles and relative bioavailability and bioequivalence.

Authors:  S A Marston; J E Polli
Journal:  Pharm Res       Date:  1997-10       Impact factor: 4.200

4.  Multivariate Assessment for Bioequivalence Based on the Correlation of Random Effect.

Authors:  Hyungmi An; Dongseong Shin
Journal:  Drug Des Devel Ther       Date:  2021-08-23       Impact factor: 4.162

5.  Bioequivalence testing by statistical shape analysis.

Authors:  Luis Marcelo Pereira
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-06-07       Impact factor: 2.410

Review 6.  Evaluation of Excipient Risk in BCS Class I and III Biowaivers.

Authors:  Melissa Metry; James E Polli
Journal:  AAPS J       Date:  2022-01-05       Impact factor: 4.009

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.